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ABSTRACT
The purpose of this study was to evaluate whether follicular histology in large cell lymphoma influences
treatment outcomes after autologous stem cell transplantation (ASCT). It remains an area of controversy
whether the natural history of follicular large cell lymphoma (FLCL) is akin to diffuse large cell lymphoma
(DLCL) with curative potential or is more similar to indolent follicular lymphomas with a pattern of late
relapses after intensive chemotherapy. Although ASCT is a potentially curative treatment for patients with
recurrent DLCL, the effectiveness of this approach in patients with FLCL is unclear. We undertook a
retrospective analysis of 332 patients with large cell lymphoma who underwent ASCT at the City of Hope
Comprehensive Cancer Center. With a median follow-up of 31 months, the projected 10-year overall survival
and disease-free survival were similar between patients with FLCL and DLCL. Analysis of prognostic factors
demonstrated that although age, chemotherapy refractoriness, and disease status at the time of ASCT were
predictive of overall survival/disease-free survival, follicularity did not influence the outcome. Furthermore, the
similar plateau in the survival curve for the DLCL and FLCL patients suggests that the behavior of FLCL is
similar to that of DLCL and that FLCL is potentially curable with ASCT.
© 2006 American Society for Blood and Marrow Transplantation
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Over the past 20 years, several classiﬁcation schemes
ave been developed for non-Hodgkin lymphoma
NHL) that are based on the observation that the
linical behavior of various follicular lymphomas
an be highly variable and on the need for a more
recise and reproducible system to guide clinicians.
t present, the curative potential of follicular large
ell lymphoma (FLCL), otherwise known as follic-
lar grade 3 NHL in the Revised European-Amer-
can classiﬁcation (REAL) schema, remains an area
f controversy [1]. Some series suggest that FLCL
ehaves as an indolent lymphoma characterized by
ate relapses after chemotherapy [2]. Other investi-
ators have demonstrated high complete remission
ates and plateaus in disease-free survival (DFS) s
B&MThen these patients were treated with an anthracy-
line-based regimen [3-5].
The role of autologous stem cell transplantation
ASCT) for this histologic subtype is also unclear. For
atients with relapsed NHL, a prospective random-
zed study has demonstrated that high-dose chemo-
herapy/radiotherapy with ASCT is superior to con-
entional salvage therapy [6]. However, the number of
atients with FLCL included in the study was small;
ence, this question remain unanswered: is ASCT
urative, or are there continued late relapses, as occur
ith other follicular histologic categories [7]? Several
etrospective series have addressed this question, but
ith conﬂicting results [8,9]. In the Nebraska series,
atients with good-prognosis FLCL had an improved
urvival compared with a similar group of patients
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6ith diffuse large cell lymphoma (DLCL) [8]. In con-
rast, the series from Princess Margaret Hospital
ound no prognostic signiﬁcance to FLCL versus
LCL histological ﬁndings [9]. Because of these con-
icting results, we evaluated this question in a larger
eries of patients with sufﬁcient long-term follow-up
o capture late relapses.
ATERIALS AND METHODS
This was a retrospective study of 332 patients with
arge cell NHL who underwent ASCT at the City of
ope Comprehensive Cancer Center between De-
ember 1987 and November 2002. Fifty-ﬁve patients
ad FLCL, and 277 had DLCL. All biopsy specimens
ere reviewed at the City of Hope by an expert he-
atopathologist, and the most recent biopsy sample
efore ASCT was classiﬁed according to the REAL
chema. All FLCL patients had either a core biopsy or
xcisional biopsy for diagnosis, and 14 of these pa-
ients underwent another biopsy at time of relapse
efore transplantation. Patients with T-cell lympho-
as were excluded from analysis. Informed consent
as obtained from patients, in compliance with insti-
utional standards. Patients were considered eligible
or transplantation if they had not achieved an initial
omplete remission or if they relapsed after attaining
complete remission with standard-dose chemother-
py. In addition, patients in ﬁrst complete remission
ho had high-risk features, as deﬁned by the Interna-
ional Prognostic Index (IPI), were also eligible for
ransplantation [10].
The median age at transplantation was 52 years
range, 27-63 years) and 46 years (range, 12-75 years)
or the FLCL group and the DLCL group, respec-
ively (P  .005). Other patient and disease character-
stics are summarized in Table 1. A higher proportion
f patients in the FLCL group had relapsed disease at
he time of ASCT. However, both groups had com-
arable numbers with a chemotherapy-sensitive re-
apse. Sensitive relapse was deﬁned as at least a 50%
eduction in bidimensional measurements of the size
f the tumor with the use of conventional salvage
herapy. Patients were considered to be in partial
able 1. Patient Characteristics
Variable FLCL
edian age, y (range) 52
isease status 1 CR/1 PR
IF 3
REL 40
hemosensitive REL 16
one marrow involvement at diagnosis 13
TBI conditioning 25
ulky disease >10 cm 9R indicates complete remission; PR, partial remission; REL, relapse; Un
42emission if they had a 50% reduction in the diam-
ter of all measurable lesions for at least 3 months and
esolution of disease-related symptoms. Patients who
ad 50% reduction, reappearance of disease-related
ymptoms, or measurable growth of disease during
herapy or within 2 months of completion of treat-
ent were considered to have induction failure. There
ere more patients with bulky disease in the DLCL
roup, and there was more bone marrow involvement
n the FLCL group. The IPI score was known in 143
atients. The median score was 2 in the FLCL group
nd 3 in the DLCL group. Cytogenetic information
as available for 39 of the FLCL patients. Four of
hese patients had the 14,18 translocation: 2 in bone
arrow and 2 in lymph nodes.
Transplantation screening criteria included nor-
al cardiac function (deﬁned as an ejection fraction
50% by either echocardiogram or multiple gated
cquisition scan), adequate pulmonary function (dif-
usion capacity 50% or forced expiratory volume in
second 75% of predicted), and adequate renal
unction (24-hour creatinine clearance 60 mL/min).
atients were screened for hepatitis A, B, and C virus,
hough this was not an exclusion criterion. They were
equired to have no bone marrow involvement with
ymphoma on their pretransplantation marrow except
or patients with discordant lymphoma, who had5%
esidual marrow involvement. There was no upper age
imit on transplantation.
Bone marrow and/or peripheral blood progenitor
ells (PBPCs) were collected. Methods for marrow and
BPC collection have been previously described [11].
o purging was performed of either marrow or PBPCs.
atients with prior bone marrow involvement at diag-
osis received PBPCs. Before 1989, patients received a
ombination of bone marrow and PBPC. Starting in
991, all patients received PBPCs preferentially.
Patients were treated with 1 of 3 transplant con-
itioning regimens. The choice of regimen was based
n their prior chemotherapy sensitivity, age, and radia-
ion history. The radiation-based regimen consisted of
otal body irradiation 1200 cGy delivered in split frac-
ions, followed by etoposide 60 mg/kg (adjusted body
eight) and cyclophosphamide 100 mg/kg (ideal body
) DLCL (n  277) P Value
3) 46 (12-75) .005
0%) 1 CR/PR: 112 (41%) <.001
IF 61 (22%)
REL 101 (37%)
Unk 4 (1%)
42 (70%) .13
35 (13%) .03
146 (67%) .92
92 (39%) .009(n  55
(27-6
: 11 (2
(6%)
(74%)
(40%)
(23%)
(66%)
(19%)k, unknown; FTBI, fractionated total body irradiation.
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Follicularity in Large Cell Lymphoma
Beight). The chemotherapy regimen was either (1) cy-
lophosphamide 100mg/kg (ideal body weight), carmus-
ine 150 mg/m2  3, and etoposide 60 mg/kg (adjusted
ody weight) or (2) carmustine 150 mg/m2  2, etopo-
ide 200 mg/m2  8, cytarabine 200 mg/m2  8, and
elphalan 140 mg/m2  1.
Autologous marrow or PBPCs were transported to
he bedside in the vapor phase of liquid nitrogen,
hawed at bedside in a water bath, and reinfused ac-
ording to standard institutional guidelines on day 0.
ranulocyte colony-stimulating factor was started on
ay 1 at a dose of 5 g/kg (until 1999, when as
tandard practice it was started on day 5 at the same
ose) and continued until patients reached an absolute
eutrophil count 500 l for 3 consecutive days.
Supportive care with prophylactic antimicrobials,
ntifungals, and low-dose heparin for veno-occlusive
isease prophylaxis was administered according to in-
titutional guidelines [11]. The only major change in
upportive care during the time period covered in the
tudy was a change from vancomycin/neomycin to
evoﬂoxacin in 1996 to minimize risks of vancomycin-
esistant enterococcus.
athology Review
All pathology specimens from diagnosis and the
ost recent pretransplantation biopsy sample were
eviewed at the City of Hope and classiﬁed according
o the REAL classiﬁcation. Subclassiﬁcation of the
ollicular lymphomas was performed according to the
ann and Berard criteria, which require that 15
ells per high-power ﬁeld (0.159 mm2) be large non-
leaved cells [12]. T-cell phenotypes were excluded on
he basis of immunohistochemistry.
isease Response Evaluation
Patients had a pretransplantation staging evalua-
ion within 28 days of enrollment onto a transplanta-
ion protocol that consisted of computed tomographic
cans, bone marrow biopsy, and clinical documenta-
ion of disease. The Ann Arbor staging system was
sed. Posttransplantation disease evaluation was per-
ormed with computed tomographic scans at approx-
mately 1 to 2 months after transplantation and then
very 6 months for the ﬁrst 2 years. Subsequently
cans were performed yearly for 5 years after ASCT
nd sooner if clinically indicated. Disease status was
ssessed according to conventional criteria, as previ-
usly described [11].
tatistical Methods
Demographic and disease characteristics were
ummarized for all patients by using simple descrip-
ive statistics. Two-sided 2-sample t tests were used
or comparing means between the 2 histologic groups.
urvival estimates were calculated according to the
B&MTroduct-limit method, and 95% conﬁdence intervals
ere calculated by using the logit transformation with
reenwood’s variance estimate [13]. Factors possibly
ssociated with overall survival (OS), DFS, and relapse
ere examined by univariate and multivariate Cox
egression analysis [14]. The assumption of propor-
ionality of the hazard ratio was tested for each vari-
ble. The variables tested included age at transplanta-
ion, sex, bulky disease at diagnosis, stage at diagnosis,
B” symptoms, marrow involvement, increased lactate
ehydrogenase, and extranodal disease, each at diag-
osis and relapse; number of prior chemotherapy reg-
mens; prior radiation therapy; IPI score; disease sta-
us; chemosensitivity; and conditioning regimen. The
azard ratio was calculated for each variable, along
ith the 95% conﬁdence intervals. Multivariate anal-
ses were performed by using a stepwise model selec-
ion and model prediction with a threshold P .20 for
ariable entry and P  .05 for retention.
OS was deﬁned as the time from transplantation
ntil death or last contact. Time to relapse was de-
ned as the time from transplantation until conﬁrmed
elapse or last contact. DFS was deﬁned as the time
rom transplantation until relapse or death if the pa-
ient did not relapse or until last contact if the patient
id not die or relapse.
ESULTS
The median follow-up was 31 months for all sur-
iving patients (range, 0.7-175 months). The median
ollow-up in the FLCL group was 19 months (range,
-146 months) and was 34 months (range, 0.7-175
onths) for DLCL patients. The projected 10-year
S is 48% (95% CI, 38%-58%) for all patients, 58%
95% CI, 38%-74%) for FLCL, and 46% (95% CI,
4%-57%) for DLCL (P  .27; Figure 1). The pro-
ected 10-year DFS is 36% (95% CI, 27%-46%) for all
atients, 27% (95%CI, 10%-48%) for FLCL, and 38%
95% CI, 28%-49%) for DLCL (P  .70; Figure 2).
auses of death were as follows: lymphoma recurrence
77%), transplant-related mortality (19%), and sec-
ndary malignancies (4%).
Univariate analysis of the combined group dem-
nstrated that the IPI score, bulky disease at diagnosis,
ge, disease status at ASCT, and type of conditioning
egimen (fractionated total body irradiation versus
hemotherapy alone) were predictive of both OS and
FS. However, histological type, ie, follicular versus
iffuse, was not predictive of either OS or DFS. Mul-
ivariate analysis of the combined group resulted in 1
iable model, which showed chemorefractoriness (rel-
tive risk (RR), 3.28; 95% CI, 2.18-4.93) and age (RR,
.02; 95% CI, 1.01-1.05) as predictive of DFS (P 
0001 and P  .003, respectively).In subgroup analysis of patients who underwent
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6ransplantation in sensitive relapse, the 1-year OS was
4% (95% CI, 49%-75%) for all patients, 66% (95%
I, 37%-85%) for FLCL, and 62% (95% CI, 46%-
6%) for DLCL patients (P  .33). The 1-year DFS
as 53% (95% CI, 39%-65%) for all patients, 62%
95% CI, 35%-81%) for FLCL, and 50% (95% CI,
4%-64%) for DLCL (P  .92).
Subgroup analysis of the ﬁrst complete remission/
artial remission patients was also performed. The
-year OS was 86% (95% CI, 78%-91%) for all pa-
ients, 91% (95% CI, 51%-99%) for FLCL patients,
nd 86% (95% CI, 77%-91%) for DLCL patients
P  .76). The 1-year DFS was 78% (95% CI,
9%-85%) for all patients, 73% (95% CI, 37%-
0%) for FLCL, and 79% (95% CI, 70%-86%) for
LCL (P  .18).
Figure 1. Follicular large cell versus diffuseFigure 2. Follicular large cell versus diffuse large ce
44When the groups were analyzed separately by
ultivariate analysis, bone marrow involvement and
he number of prior chemotherapy regimens were sig-
iﬁcant predictors of OS/DFS in the FLCL group. In
he DLCL group, bone marrow involvement at relapse,
he IPI score before ASCT, age30 years at ASCT, and
nduction failure before ASCT were predictive of OS/
FS. Factors that were associated but did not reach
tatistical signiﬁcance included bulky disease at diagnosis
nd extranodal disease at diagnosis.
ISCUSSION
FLCL is an uncommon malignancy that repre-
ents between 3% and 7% of all NHLs [15]. None-
cell lymphoma: overall survival (n  332).ll lymphoma: disease-free survival (n  332).
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Follicularity in Large Cell Lymphoma
Bheless, it remains a controversial disease in terms of
iagnosis, treatment, and prognosis. For example, in
he Working Formulation, FLCL is classiﬁed as an
ntermediate-grade lymphoma, whereas in the REAL
lassiﬁcation it is designated as follicular center lym-
homa grade 3 [1]. Other studies have further at-
empted to deﬁne prognosis by evaluating the clinical
igniﬁcance of the subdivision of follicular grade 3
nto 3a and 3b [16,17]. Cytogenetic studies have dem-
nstrated that there is a high frequency of t(14,18) in
ollicular 3a (73%) but a relatively low frequency in
ollicular 3b (13%). Although the presence or absence
f this translocation does not have prognostic signif-
cance for DFS, it does demonstrate the heterogeneity
f the follicular lymphomas and may partially explain
nconsistencies in the clinical behavior of FLCL [17].
For example, do these lymphomas behave clini-
ally like DLCL, or do they have a pattern of late
elapses that resemble indolent lymphomas? Several
etrospective studies have attempted to answer this
asic question and have tried to deﬁne the optimal
hemotherapy regimen. Initial series demonstrated
he superiority of anthracycline-containing regimens
or FLCL similar to DLCL. In a report of 96 patients
reated at Stanford University, approximately half the
atients received a doxorubicin-containing regimen.
he 10-year OS was 65% in this group, versus 42% in
he group treated with nonanthracyline regimens [18].
ther studies have conﬁrmed that long-term outcome
s similar for DLCL and FLCL patients treated with
oxorubicin-based regimens. A series of 100 patients
rom M.D. Anderson Cancer Center, all treated with
cyclosphosphamide, adriamycin, vincristine, pred-
isone (CHOP)-bleomycin–based regimen, reported
72% OS at 5 years with a trend toward a plateau in
ailure-free survival. The IPI score was predictive of
rognosis in this group. Long-term follow-up of a
ubgroup treated from 1973 to 1981 showed an OS of
1% at 15 years [3]. This outcome is similar to that of
LCL patients treated with CHOP-bleomycin at the
ame institution [19]. A French series of patients
reated with a combination chemotherapy regimen on
he LNH87 trial included 89 patients with FLCL.
hen they were compared with DLCL patients in the
rial, there was no signiﬁcant difference in 5-year OS
nd DFS [20].
In contrast to the aforementioned studies, other
nvestigators have suggested that there is no plateau in
FS and that there is a continuous pattern of relapse,
nd this would be more akin to the behavior of indo-
ent lymphomas. For example, the Nebraska study
roup reported on stage I and II follicular lymphoma
atients. Seventy-ﬁve percent of these patients had
LCL. The investigators did not see a plateau in OS
r event-free survival in this group [21]. Similarly, a
outh West Oncology Group study of 389 patients,
hich included 53 patients (14%) with FLCL, showed t
B&MTcontinuous decline in the OS curve and a 10-year
stimated OS of 37% for the FLCL subgroup. How-
ver, this group did not include stage I and II patients
nd also did not report the number of patients who
ied of non–lymphoma-related causes [2].
The role of ASCT for FLCL also remains unde-
ned. Dose-intensive chemotherapy/radiotherapy with
SCT has become accepted salvage therapy for patients
ith relapsed DLCL. The superiority of this approach
ver conventional-dose chemotherapy for relapsed
isease has been conﬁrmed in randomized trials [6]. In
ddition, prognostic factors for DLCL after ASCT
ave been identiﬁed. These factors include IPI at the
ime of relapse, bulky disease, and chemosensitivity
22-24]. The use of ASCT for indolent lymphomas
as also been extensively studied. Factors inﬂuencing
SCT outcome for these patients include chemosen-
itivity, tumor burden, the number of prior chemo-
herapy regimens, and BCL-2 status after ASCT
7,25]. These trials also demonstrate that in contrast
o DLCL, there is no plateau in the DFS for patients
ith indolent follicular lymphomas after ASCT. Some
f these trials may have included FLCL patients.
owever, because of the small numbers of patients
nd the use of various classiﬁcation systems, it is dif-
cult to extrapolate data for this subgroup. Several
etrospective studies have looked speciﬁcally at FLCL
atients and attempted to identify prognostic factors
or outcome after ASCT. The series from Nebraska
valuated 289 patients with large cell lymphoma, 62 of
hom had FLCL. The median follow-up was 24
onths (range, 3-131 months). They found that tu-
or bulk, the number of prior chemotherapy regi-
ens, and increased lactate dehydrogenase were sig-
iﬁcantly predictive for worse failure-free survival [8].
n contrast, follicular histological results had a positive
ffect on failure-free survival.
The investigators then went on to divide patients
nto a good-prognosis group (normal lactate dehydro-
enase, 3 prior chemotherapy regimens, and non-
ulky disease). In this group, on multivariate analysis,
ollicular histology was an independent predictor of
mproved OS. In the other patients—ie, the poor-
rognosis group—follicularity had no signiﬁcant ef-
ect on outcome. Data from investigators at Princess
argaret Hospital support the latter ﬁndings [9].
hey performed a retrospective analysis on 36 pa-
ients with FLCL and compared them with 90 DLCL
atients undergoing ASCT at the same time period.
he patient characteristics were relatively evenly
atched in both groups except for more bone marrow
nvolvement in the FLCL group. Multivariate analysis
ndicated that the lymphoma subtype did not inﬂu-
nce OS or DFS. There initially seemed to be a
urvival advantage in the FLCL patients, but at 7 years
he survival curves overlapped. Failure to ﬁnd an ad-
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6antage similar to that in the Nebraska series may be
ue to patient numbers and disease characteristics,
uch as fewer good-risk patients in the Princess Mar-
aret series. For example, 31% of their patients had
ulky disease at ASCT, in contrast to 12% in the
ebraska series. In addition, 36% of their FLCL
atients had bone marrow involvement, in contrast to
4% in the Nebraska series. A series of 92 follicular
ymphoma patients from Stanford University included
4 with FLCL [26]. They reported results similar to
hose of the Nebraska group. Four-year OS and DFS
ere 58% and 49%, respectively. The number of
LCL patients was too small to allow for analysis of
rognostic factors. However, the plateau in the sur-
ival curve for this group supports the theory that in
ontrast to indolent follicular lymphomas, late re-
apses after ASCT are uncommon.
Our study conﬁrmed the Princess Margaret ob-
ervation that follicularity does not inﬂuence outcome
fter ASCT for large cell lymphoma. OS was not
igniﬁcantly different between the FLCL and DLCL
atients. Characteristics such as disease status at
SCT, chemosensitivity, and age at ASCT were the
ajor factors predictive of OS/DFS. Other signiﬁcant
actors included the IPI score, the presence or absence
f bulky disease, and the type of conditioning regimen.
ollicular histology was not a statistically signiﬁcant vari-
ble in predicting outcome. The characteristic cytoge-
etic abnormality of the 14,18 translocation was seen in
nly a minority of patients. This number was not large
nough to analyze the effect on DFS. In comparison
ith the Princess Margaret series, we had fewer pa-
ients with bulky disease in the FLCL subgroup (19%)
nd also fewer with bone marrow involvement (19%).
onetheless, we still failed to ﬁnd an advantage for
LCL histology. In addition, the plateau in the sur-
ival curve supports the notion that the natural history
f FLCL is similar to that of DLCL.
Our study and those of the Nebraska and Cana-
ian series reﬂect the limitations of the current clas-
iﬁcation systems for follicular lymphomas. We al-
eady know from DNAmicroarray studies that the IPI
core alone is not sufﬁcient to reﬂect the differences in
ehavior of DLCL [27-29]. The same likely holds true
or FLCL [29]. Hence, some of the observed differ-
nces in these retrospective studies likely reﬂect the
eterogeneity of these large cell lymphomas beyond
lassically deﬁned prognostic factors in ways that we
annot yet predict. We also recognize that this was a
eterogenous population as a result of the retrospec-
ive nature of the study. However, when we analyzed
atients by disease status, we still did not see a differ-
nce in OS or DFS between FLCL and DLCL. Thus,
ollicularity does not seem to predict outcome after
SCT for large cell lymphoma.
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